Pharmaceutical shippers are redesigning supply chains around nearshoring and diversified sourcing, and logistics providers that cannot deliver contextual data intelligence alongside temperature-controlled capacity risk losing the business. That is the core commercial shift emerging across the pharma cool chain, driven by medicine shortages, active pharmaceutical ingredient (API) constraints and geopolitical volatility that exposed the fragility of globally stretched networks.

Price still matters in pharma logistics tenders, but continuity, compliance and disruption management now sit in the same evaluation framework. Laetitia Chery, Vice President Pharma & Healthcare EMEA at JAS, said: "One of the biggest transformations we have experienced in recent years has been the impact of medicine shortages across the market. This is not something the industry can afford to leave unresolved... We have had to rethink how we secure supply chains and develop more resilient solutions for the future."

Yannick Morel, Director of Distribution at UPSA, added: "Its impact is still shaping the way we think about supply chains today, particularly around end-to-end visibility, nearshoring and reshoring strategies. It fundamentally changed how we approach resilience and long-term continuity across pharmaceutical logistics."

What does health sovereignty mean for cargo flows?

European governments and healthcare organisations are scrutinising where critical medicines and APIs are produced, how dependent supply chains are on overseas manufacturing, and how quickly alternative capacity could be activated during disruption. The objective is not to eliminate international trade but to reduce excessive dependency on single regions.

Chery framed the timeline starkly: "It takes around four or five years to bring local supply back into Europe in a meaningful way, with products that are ultimately enhanced." She described the shift as "health sovereignty" — a strategic push to produce and secure key APIs closer to home within Europe.

Morel said the commercial logic has changed: "It is no longer sufficient to rely on traditional sourcing models from ten years ago; there is now a need to incorporate additional cost structures and decision layers that were previously not standard." A network built solely on minimum cost looks different once the cost of shortage, disruption or emergency procurement enters the calculation.

For carriers and forwarders, the consequences are physical as much as commercial. New manufacturing locations require validated warehouses, temperature-controlled transport, compliant handling and reliable connections between raw material suppliers, plants and healthcare markets. Biologics, personalised medicines and other high-value therapies tighten requirements around environmental control and traceability further.

Why is visibility no longer enough?

Multi-sourced networks with alternative routes create more options — and more information demands. Yet the industry has spent years investing in visibility without resolving the data fragmentation underneath it. Manufacturers, forwarders, airlines, ground handlers and logistics providers each generate valuable data in separate systems.

Rouven Dochtermann, Head of Operations at tempmate, said: "When I first entered this industry, I realised there were data silos everywhere. The real value does not come from simply collecting vast amounts of information, but from contextualising it properly and aggregating it in the right way."

His colleague Daniel Fiedrich, Head of Customer Solutions at tempmate, made the scale argument: "If you only analyse two shipments, you cannot make reliable predictions, but if you can evaluate thousands of shipments, you can build far more accurate forecasting and operational insights."

A single temperature reading has limited strategic value. Combined with route history, handling events, weather conditions and facility performance, it becomes part of a wider risk assessment — and a potential differentiator for providers as customers demand more than basic tracking. Data-sharing must remain governed, not unrestricted, to protect confidentiality and regulatory integrity.

Can AI deliver before the data is ready?

Boards and investors increasingly expect logistics companies to demonstrate an AI strategy even where digital maturity remains inconsistent. Michael Sluypers, CEO at emineo International SA, was blunt about the disconnect: "There is pressure to label initiatives as AI because investors want to see modernisation strategies tied to AI investment. But companies cannot forget the baseline capabilities they need first. Without the right foundations, the technology will not create value."

He described a pragmatic model: "Today, we still carry out the scenario planning ourselves and then use AI to evaluate those scenarios against the available information. That creates far more informed decision-making without removing the human role."

Sluypers also predicted how adoption will spread: "In pharma, we already see risk being transferred towards smaller companies and start-ups that are developing new products and technologies. I believe AI adoption will follow a similar pattern because innovation at this stage still carries significant risk. Large companies are not yet comfortable taking those risks directly." Larger organisations will act as followers rather than early adopters until standards mature.

How do partnerships fill the capability gap?

The combination of physical infrastructure, monitoring, data management, regulatory expertise and technology forms a complex ecosystem that few providers can build alone. Fiedrich said: "We do not need to be experts in everything ourselves, but we do need to know the right experts and work closely with them to deliver the best possible service to our clients."

Dochtermann pointed to where this leads: "Once that contextual layer is in place, it becomes possible to unify data intelligence and use workflow automation to solve problems autonomously. That is where the industry begins moving from visibility towards true operational intelligence."

Chery also warned that pandemic risk has not receded: "In the future, we are likely to face more pandemics," which she linked to environmental pressures and changing disease transmission patterns — reinforcing the localisation agenda.

The direction of travel is clear: regionalised production will keep reshaping pharma cargo flows, and competitive advantage will accrue to cool-chain operators that pair validated physical infrastructure with structured, shared data — well before the AI layer earns its boardroom billing.